vention has almost completely eradicated thalassaemia in Cyprus and Sardinia and control programmes are now Genetic technology has caught the imagination of many. Those involved in developing health strategies for counbeing initiated across Africa. The success of such strategies will probably make the need for gene therapy tries with lesser resources are often obsessed with organisational structures and have little vision of future techobsolete. Persuasion, education and organisation have been the key contributing factors. Similar approaches are nology. Indeed, politicians and their advising civil servants can barely keep abreast with best existing pracnecessary for other hereditary disorders. Genetic factors are also important in the aetiology of a tices. The high cost of molecular research and its requirement for a highly educated workforce acts as a powerful number of chronic diseases that because of ageing are now becoming a far more important cause of disability. disincentive for poorer countries to get involved at all. And yet in a world continuing to shrink due to the comFurthermore, unless checked, the facilities to treat these diseases will consume vast amounts of the healthcare munications revolution, people are hearing very positive messages about gene therapy as a new panacea. The budget. It is imperative to implement preventive strategies where at all possible. The key to success in cancer eradication of inherited diseases, the cure for cancer, and a reduction in the inexorable ageing process are all promprevention, for example, is careful targeting. Clearly there is little point telling the dark-skinned village ised through the new genetics. How best can a strategy be evolved to inform and educate not just healthcare profisherman of Southern India to avoid sunbathing on the beach. Targeted prevention programmes are very costfessionals but also policymakers and populations to distinguish potentially useful ways forward from simple effective and can be shared by different countries with similar cancer patterns. Countries with limited resources hype?
It is clear that there has been a considerable reduction need not keep reinventing the wheel. Prevention packages can be tailored and adapted widely. To do this we in the mortality, disability and morbidity caused by infection and malnutrition. This has dramatically changed the need good data of incidence in relation to geography. Descriptive epidemiology provides a fertile hunting age distribution of many populations and hence the diseases that will affect them. By the year 2020 there will be ground for patterns of carcinogenesis. Relating genetic changes in cancer to their cause and geography -the major shifts in global disease patterns, with cancer and cardiovascular disease dominating all currencies of sufemerging discipline of molecular epidemiology -will complete the circle and point the way to specific interfering. An amazing 31 countries are predicted to have a more than 100% per cent increase in their population ventions. The future of prevention will almost surely be about using such techniques to target carefully prevenaged over 65 years.
1 Hereditary disease will also be a major health burden, affecting the prosperity of whole tive strategies to those who would benefit most. In the post-genomic era it is likely that cancer prevention profamilies. Community genetics services are relatively inexpensive and yet highly cost effective. There is an urgent grammes, at least in developed countries, will be completely individualised -a combination of genetic, need for more international collaboration in this rapidly evolving area. In 1995 the World Health Organisation environmental and lifestyle data will be used to construct very specific personalised messages. Such concepts apply (WHO) produced a timely document examining ethical issues in medical genetics and in the provision of genetic equally to the prevention of other diseases where genetics and lifestyle are important and interacting components. services. 2 It recommended that clinical genetic services be an integral part of basic health care. All governments Screening in many countries is also an important tool. Careful targeting is required. Again the cost of the techshould examine the provision of existing services and anticipate developments such as the Human Genome nology required must match the gain. Low cost, direct inspection techniques for oral and cervical cancer by Initiative. The difficulty is the disparate nature of the world with wide cultural, economic, religious and trahealth workers seem attractive to achieve tumour downstaging, and hence, better survival results. Unfortunately, ditional differences. 3 The use of prenatal diagnosis and abortion as a tool to reduce disease burden is simply not the evaluation of such programmes in India and China has shown surprisingly poor results in terms of overall possible in some societies.
The haemoglobinopathies have proven a convenient effectiveness. A major cost in instituting any screening procedure is simply getting the message to the people model to work out an approach to the control of chronic childhood diseases in developing countries. Of 300 000 and then developing the logistics, often under difficult conditions. Cultural barriers may be insurmountable children born annually with major haemoglobinopathies, without better education, especially of girls, who as itt's lymphoma and testicular cancer fare less well in poorer countries. Getting good results here has to be the mothers will become responsible for family health. Low priority. Using expensive but ineffective drugs for hepatechnology tests have low specificity so flooding already toma, stomach, lung and oesophageal cancers is a luxury hard pressed secondary care facilities with patients with that cannot be afforded, even in the guise of research. nonlife-threatening abnormalities. Again, genetic inforThere are no data to suggest that patients with one of mation could be used to refine population groups for these cancers do better in Switzerland than Mozambique, screening.
currently the world's richest and poorest countries. Gene therapy does offer a potential way forward for Clearly, genetic intervention cannot convey immordealing with noncommunicable diseases. Currently, the tality. It almost certainly will be used to reduce disease main clinical emphasis is on cancer with cystic fibrosis symptoms and prolong active healthy life especially in and cardiovascular disease lagging some way behind.
patients with chronic disease. It is vital that planners now Cancer is an obvious current target for three reasons.
start anticipating the likely technical progress in this area. First, little impact is being made by classical chemoHealth economists have developed sophisticated tools to therapy. Our understanding of the molecular pathology assess cost-effectiveness of interventions. These need to of the disease has dramatically increased. And of course, be applied to emerging technologies as well. Gene therthere are abundant research funds -reflecting perhaps apy holds tremendous promise. At this stage the richer the public's desperation to search for a cure at all costs.
nations need to develop products for international collabThe key problem of vector development can be eluciorative clinical trials. Ethical guidelines like reagents dated using cancer as a model and then easily applied to need to be freely transferred to prevent wasteful protracother situations. It is unlikely that significant health gains ted discussions. The WHO could play a central role in from the use of this embryonic technology will be seen approving international standards such as those outlined for several years. It is therefore vital that poorer countries in the recent Points to Consider documents. 4 The effective resist the temptation to enter this highly competitive integration into routine practice across a wide economic arena alone. Partnerships and free information exchange spectrum will be a considerable future challenge. would be a better solution. As gene therapy reagents become available there is no reason why clinical trials K Sikora cannot be carried out internationally using well-WHO Cancer Control Programme respected ethical practices.
IARC, Lyon, 69372 France The treatments of the next century will be rationally on secondment from Department of Clinical Oncology designed, less toxic and more effective. But the costs of Imperial College School of Medicine cancer care as practised in the established market econHammersmith Hospital, London, UK omies even now far outstrip the resources of many countries. We have to look at ways to keep costs down and
